COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,621 Articles (22,913 medRxiv, 8,708 bioRxiv)

Most recent first Previous |  Page 1328: Articles 13271-13280  | Next

Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay
Junker, D., Dulovic, A., Becker, M., Wagner, T. R., Kaiser, P. D., Traenkle, B., Rothbauer, U., Kienzle, K., Bunk, S., Strümper, C., Häberle, H., Schmauder, K., Malek, N., Althaus, K., Koeppen, M., Bitzer, M., Göpel, S., Schneiderhan-Marra, N.
10.1101/2021.08.20.21262328 — Posted: 2021-08-22
Seroresponse to SARS-CoV-2 vaccines among maintenance dialysis patients
Hsu, C. M., Weiner, D. E., Aweh, G. N., Manley, H. J., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K., Chin, A., Gladish, R., Salman, L., Johnson, D., Lacson, E. K.
10.1101/2021.08.19.21262292 — Posted: 2021-08-22
Inhaled nitric oxide use in COVID19-induced hypoxemic respiratory failure.
Giri, A. R., Yarrarapu, S. N. S., Kaur, N., Hochwald, A. P., Crook, J., Helgeson, S., Harrison, M. F., Patel, N., Guru, P. K., Lowman, P., Moreno-Franco, P., Lee, A., Sanghavi, D. K.
10.1101/2021.08.19.21262314 — Posted: 2021-08-21
Can a vaccine-led approach end the NSW outbreak in 100 days, or at least substantially reduce morbidity and mortality?
Bablani, L., Wilson, T., Andrabi, H., Sundararajan, V., Ait Oukarim, D., Abraham, P., Thompson, J., Blakely, T.
10.1101/2021.08.18.21262252 — Posted: 2021-08-21
Effect of familiarity with COVID-19 infection--history of infection or close contact--on outing behaviors when a state of emergency is declared
MORI, T., Nagata, T., Ikegami, K., Hino, A., Tateishi, S., Tsuji, M., Matsuda, S., Fujino, Y., Mori, K.
10.1101/2021.08.20.21262364 — Posted: 2021-08-21
Using routine emergency department data for syndromic surveillance of acute respiratory illness before and during the COVID-19 pandemic in Germany, week 10-2017 and 10-2021
Boender, T. S., Cai, W., Schranz, M., Kocher, T., Wagner, B., Ullrich, A., Buda, S., Zoellner, R., Greiner, F., Diercke, M., Grabenhenrich, L.
10.1101/2021.08.19.21262303 — Posted: 2021-08-21
Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations? Results from population data from Bavaria, Germany
Gomes, D., Beyerlein, A., Katz, K., Hoelscher, G., Nennstiel, U., Liebl, B., Ueberla, K., von Kries, R.
10.1101/2021.08.19.21262266 — Posted: 2021-08-21 Discussion: Onsite
Self-testing and vaccination against COVID-19 to minimize school closure
Colosi, E., Bassignana, G., Contreras, D. A., Poirier, C., Cauchemez, S., Yazdanpanah, Y., Lina, B., Fontanet, A., Barrat, A., Colizza, V.
10.1101/2021.08.15.21261243 — Posted: 2021-08-21 Discussion: Offsite
The burden of isolation to the individual: a comparison between isolation for COVID-19 and for other influenza-like illnesses in Japan
Tsuzuki, S., Ohmagari, N., Beutels, P.
10.1101/2021.08.19.21262267 — Posted: 2021-08-21
Regional comparisons of COVID reporting rates, burden, and mortality age-structure using auxiliary data sources
Van Gordon, M. M., Mwananyanda, L., Gill, C. J., McCarthy, K. A.
10.1101/2021.08.18.21262248 — Posted: 2021-08-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).